scholarly journals Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

2016 ◽  
Vol 6 (1_suppl) ◽  
pp. S5-S14 ◽  
Author(s):  
Reiner Frey ◽  
Corina Becker ◽  
Sigrun Unger ◽  
Anja Schmidt ◽  
Georg Wensing ◽  
...  
Keyword(s):  
Oral Dose ◽  
Single Oral Dose ◽  
Guanylate Cyclase ◽  
Hepatic Impairment ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator

Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator

2021 ◽  
pp. 127886
Author(s):  
Glen R. Rennie ◽  
Timothy C. Barden ◽  
Sylvie G. Bernier ◽  
Andrew Carvalho ◽  
Renee Deming ◽  
...  
Keyword(s):  
Carboxylic Acid ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator

scholarly journals Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

2017 ◽  
Vol 60 (12) ◽  
pp. 5146-5161 ◽  
Author(s):  
Markus Follmann ◽  
Jens Ackerstaff ◽  
Gorden Redlich ◽  
Frank Wunder ◽  
Dieter Lang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator

scholarly journals Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension

2015 ◽  
Vol 24 (136) ◽  
pp. 272-282 ◽  
Author(s):  
Marius M. Hoeper
Keyword(s):  
Pulmonary Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Phase Iii ◽  
Current Evidence ◽  
Endothelin Receptor ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Thromboembolic Pulmonary Hypertension ◽  
Soluble Guanylate Cyclase Stimulator

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but life-threatening disease resulting from unresolved thromboembolic obstructions. Pulmonary endarterectomy (PEA) surgery is the gold-standard treatment as it is potentially curative; however, not all patients are deemed operable and up to one-third have persistent or recurrent CTEPH after the procedure. Pulmonary arterial hypertension (PAH) and CTEPH have similar clinical presentations and histopathological features, so agents shown to be effective in PAH have often been prescribed to patients with CTEPH in the absence of proven therapies. However, clinical evidence for this strategy is not compelling. A number of small uncontrolled trials have investigated endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase type 5 inhibitors in CTEPH with mixed results, and a phase III study of the endothelin receptor antagonist bosentan met only one of its two co-primary end-points. Recently, however, the soluble guanylate cyclase stimulator, riociguat, was approved in the USA and Europe for the treatment of inoperable or persistent/recurrent CTEPH following positive results from the phase III CHEST study (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial). This article reviews the current evidence for the use of pharmacological therapies in CTEPH.

Sign in / Sign up

Export Citation Format

Share Document